Pan-PPAR Agonist 'Promising' for NASH Patients

(MedPage Today) -- Patients with active nonalcoholic steatohepatitis (NASH) who received the investigational oral drug lanifibranor (IVA337) showed greater reduction in disease activity compared to placebo, a randomized phase IIb trial found....